NCT02148328View on ClinicalTrials.gov

Safety, Tolerability, and Immunogenicity Study of a Cell-based Virosomal Influenza Vaccine in Healthy Adults

PHASE1CompletedINTERVENTIONAL
Enrollment

240

Participants

Timeline

Start Date

May 31, 2014

Primary Completion Date

October 31, 2014

Study Completion Date

October 31, 2014

Conditions
Influenza
Interventions
BIOLOGICAL

Trivalent virosomal influenza vaccine

Trivalent virosomal influenza vaccine will be administered intramuscularly on Day 1 in healthy participants.

BIOLOGICAL

Commercial vaccine 1

Trivalent commercial virosomal influenza vaccine will be administered intramuscularly on Day 1 in healthy participants.

BIOLOGICAL

Quadrivalent virosomal influenza vaccine

Quadrivalent virosomal influenza vaccine will be administered intramuscularly on Day 1 in healthy participants.

BIOLOGICAL

Commercial vaccine 2

Quadrivalent commercial influenza vaccine will be administered intramuscularly on Day 1 in healthy participants.

Trial Locations (4)

Unknown

Aalst

Ghent

Merksem

Wilrijk

All Listed Sponsors
lead

Crucell Holland BV

INDUSTRY

NCT02148328 - Safety, Tolerability, and Immunogenicity Study of a Cell-based Virosomal Influenza Vaccine in Healthy Adults | Biotech Hunter | Biotech Hunter